Disclosures
GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer
Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer,
BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees
are directly received personally.
References
1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent
risk factor for stroke: the Framingham Study. Stroke.1991;22(8):983-988.
2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused
Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients
With Atrial Fibrillation: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Rhythm Society. J Am Coll Cardiol.2019;74(1):104-132.
3. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology
2018 guidelines for management of venous thromboembolism: optimal
management of anticoagulation therapy. Blood advances.2018;2(22):3257-3291.
4. Khan AA, Lip GYH. The prothrombotic state in atrial fibrillation:
pathophysiological and management implications. Cardiovascular
research. 2019;115(1):31-45.
5. Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of
venous thromboembolism: similarities with atherothrombosis and the role
of inflammation. Thrombosis and haemostasis.2015;113(6):1176-1183.
6. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW.
Cardiovascular risk factors and venous thromboembolism: a meta-analysis.Circulation. 2008;117(1):93-102.
7. Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular Risk Factors
Associated With Venous Thromboembolism. JAMA cardiology.2019;4(2):163-173.
8. Anumonwo JM, Kalifa J. Risk Factors and Genetics of Atrial
Fibrillation. Heart failure clinics. 2016;12(2):157-166.
9. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology:
atrial fibrillation in cancer. J Am Coll Cardiol.2014;63(10):945-953.
10. Chang SL, Huang YL, Lee MC, et al. Association of Varicose Veins
With Incident Venous Thromboembolism and Peripheral Artery Disease.JAMA. 2018;319(8):807-817.
11. Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P.
Venous thromboembolism and subsequent hospitalisation due to acute
arterial cardiovascular events: a 20-year cohort study. Lancet.2007;370(9601):1773-1779.
12. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with
warfarin against recurrent venous thromboembolism. Duration of
Anticoagulation Trial. N Engl J Med. 2000;342(26):1953-1958.
13. Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk
factors for deep vein thrombosis and pulmonary embolism: a
population-based study. Archives of internal medicine.2002;162(11):1245-1248.
14. Lutsey PL, Norby FL, Alonso A, et al. Atrial fibrillation and venous
thromboembolism: evidence of bidirectionality in the Atherosclerosis
Risk in Communities Study. Journal of thrombosis and haemostasis.2018;16(4):670-679.
15. Franchini M, Mannucci PM. Venous and arterial thrombosis: different
sides of the same coin? European journal of internal medicine.2008;19(7):476-481.
16. Connolly SJ, Wallentin L, Ezekowitz MD, et al. The Long-Term
Multicenter Observational Study of Dabigatran Treatment in Patients With
Atrial Fibrillation (RELY-ABLE) Study. Circulation.2013;128(3):237-243.
17. Robertson L, Yeoh SE, Ramli A. Secondary prevention of recurrent
venous thromboembolism after initial oral anticoagulation therapy in
patients with unprovoked venous thromboembolism. The Cochrane
database of systematic reviews. 2017;12:Cd011088.
18. Lin LY, Warren-Gash C, Smeeth L, Chen PC. Data resource profile: the
National Health Insurance Research Database (NHIRD). Epidemiology
and health. 2018;40:e2018062.
19. Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside
analogues and risk of hepatitis B virus-related hepatocellular carcinoma
recurrence following liver resection. JAMA.2012;308(18):1906-1914.
20. Chang CH, Lee YC, Tsai CT, et al. Continuation of statin therapy and
a decreased risk of atrial fibrillation/flutter in patients with and
without chronic kidney disease. Atherosclerosis.2014;232(1):224-230.
21. Wang CC, Lin CL, Wang GJ, Chang CT, Sung FC, Kao CH. Atrial
fibrillation associated with increased risk of venous thromboembolism. A
population-based cohort study. Thrombosis and haemostasis.2015;113(1):185-192.
22. Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute
ischemic stroke in a National Health Insurance claims database.Journal of the Formosan Medical Association. 2015;114(3):254-259.
23. Austin PC, Fine JP. Propensity-score matching with competing risks
in survival analysis. Stat Med. 2019;38(5):751-777.
24. Schulman S, Lindmarker P, Holmstrom M, et al. Post-thrombotic
syndrome, recurrence, and death 10 years after the first episode of
venous thromboembolism treated with warfarin for 6 weeks or 6 months.Journal of thrombosis and haemostasis : JTH. 2006;4(4):734-742.
25. Guo XY, Li N, Du X, et al. Atrial fibrillation is associated with an
increased risk of myocardial infarction: Insights from a meta-analysis.Atherosclerosis. 2016;254:1-7.
26. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy
D. Impact of atrial fibrillation on the risk of death: the Framingham
Heart Study. Circulation. 1998;98(10):946-952.
27. Novo G, Lee E, Choi E-K, et al. Mortality and causes of death in
patients with atrial fibrillation: A nationwide population-based study.PloS one. 2018;13(12).
28. Heit JA. Epidemiology of venous thromboembolism. Nature
reviews Cardiology. 2015;12(8):464-474.
29. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran,
warfarin, or placebo in venous thromboembolism. N Engl J Med.2013;368(8):709-718.
30. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended
treatment of venous thromboembolism. N Engl J Med.2013;368(8):699-708.
31. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for
Extended Treatment of Venous Thromboembolism. N Engl J Med.2017;376(13):1211-1222.
32. Raskob G, Ageno W, Cohen AT, et al. Extended duration of
anticoagulation with edoxaban in patients with venous thromboembolism: a
post-hoc analysis of the Hokusai-VTE study. The Lancet
Haematology. 2016;3(5):e228-236.
33. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for
preventing recurrent venous thromboembolism. N Engl J Med.2012;367(21):1979-1987.
34. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines
for the diagnosis and management of acute pulmonary embolism developed
in collaboration with the European Respiratory Society (ERS).European heart journal. 2019.
35. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in
paroxysmal versus sustained atrial fibrillation in patients taking oral
anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.J Am Coll Cardiol. 2007;50(22):2156-2161.